Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Colorectal Neoplasms

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 68 articles: HTML format

Single Articles

October 2025
1. MEESTER RGS, Piscitello AJ, Duimstra JA, Liang PS, et al
   Comparative benefits, burdens and harms of emerging blood-based tests for colorectal cancer screening.
   J Natl Cancer Inst. 2025 Oct 6:djaf277. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. EBNER DW, Fendrick AM, Kisiel JB, Estes C, et al
   Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies.
   J Natl Cancer Inst. 2025 Oct 1:djaf209. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. EBNER DW, Estes C, Limburg PJ
   RE: Evaluating benefit-to-burden ratios of the established and emerging colorectal cancer screening strategies.
   J Natl Cancer Inst. 2025 Oct 1:djaf266. doi: 10.1093.
   PubMed    
   
   
   
4. BRAY F, Laversanne M
   Stat Bite: recent trends in colon cancer incidence at ages 25-49 vs 50-74 in 50 countries.
   J Natl Cancer Inst. 2025;117:2146-2147.
   PubMed    
   
   
   
5. IFHAM HANIF M, Sholihah MM
   RE: Effects of a high-fiber, high-fruit, and high-vegetable, low-fat dietary intervention on the rectal tissue microbiome.
   J Natl Cancer Inst. 2025;117:2142-2143.
   PubMed     Abstract available
   
   
   September 2025
6. CHENG E, Shi Q, Shields AF, Xue X, et al
   Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (alliance).
   J Natl Cancer Inst. 2025 Sep 25:djaf281. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. MEESTER RGS, Miller EA, Pinsky PF, Schoen RE, et al
   Contrasts in colorectal cancer incidence and mortality in screening trials of sigmoidoscopy versus colonoscopy (NordICC).
   J Natl Cancer Inst. 2025 Sep 14:djaf269. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. KOKER G, Ozcelik G
   RE: Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women.
   J Natl Cancer Inst. 2025 Sep 3:djaf252. doi: 10.1093.
   PubMed    
   
   
   
9. KAZEMIAN E, Mo Q, Matejcic M, Tsai YY, et al
   Genetic predisposition to persistent fatigue after a diagnosis of colorectal cancer.
   J Natl Cancer Inst. 2025 Sep 1:djaf140. doi: 10.1093.
   PubMed     Abstract available
   
   
   August 2025
10. DOWNHAM L, Laversanne M, Perdomo S, Filho AM, et al
    Increase of early-onset colorectal cancer: a cohort effect.
    J Natl Cancer Inst. 2025 Aug 23:djaf238. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. MAJOR A, Chou J, Lam H, Kim KE, et al
    Mortality after colorectal cancer among survivors of childhood cancer.
    J Natl Cancer Inst. 2025 Aug 21:djaf127. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. ZAANAN A, Bergen ES, Evesque L, Meurisse A, et al
    Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study.
    J Natl Cancer Inst. 2025 Aug 20:djaf229. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. DUHOKY R, Geitenbeek RTJ, Niccolo Piozzi G, Burghgraef TA, et al
    Ten years of robot-assisted versus laparoscopic total mesorectal excision for rectal cancer (short-term RESOLUTION).
    J Natl Cancer Inst. 2025;117:1614-1626.
    PubMed     Abstract available
    
    
    
14. FULLER S, Alexeeff S, Caan B, Goncalves MD, et al
    Early identification of weight loss trajectories in advanced cancer and associations with survival.
    J Natl Cancer Inst. 2025;117:1729-1732.
    PubMed     Abstract available
    
    
    July 2025
15. NASCIMENTO DE LIMA P, Bartholomew L, May FP, Coronado GD, et al
    The triple-effect of colorectal cancer screening: reducing deaths, government spending and mortality disparities.
    J Natl Cancer Inst. 2025 Jul 30:djaf202. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. ZHANG Y, Karahalios A, Win AK, Makalic E, et al
    A prediction model for metachronous colorectal cancer: development and validation.
    J Natl Cancer Inst. 2025 Jul 16:djaf191. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. LIEBERMAN D, Ladabaum U
    Non-invasive colorectal cancer screening: simple may be optimal.
    J Natl Cancer Inst. 2025 Jul 7:djaf171. doi: 10.1093.
    PubMed    
    
    
    
18. XU J, Lou T, Xu L
    RE: Post-diagnosis dietary and lifestyle factors and mortality outcomes among colorectal cancer patients: a meta-analysis.
    J Natl Cancer Inst. 2025 Jul 4:djaf168. doi: 10.1093.
    PubMed    
    
    
    
19. HUANG YJ, Lin JA, Chen WM, Shia BC, et al
    Metformin use and risk of colorectal cancer in patients with inflammatory bowel disease: a nationwide, Population-Based cohort study.
    J Natl Cancer Inst. 2025 Jul 2:djaf165. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. ALVAREZ J, Zambare W, George M, Garcia R, et al
    Utilizing Patient Input in Rectal Cancer Trial Design.
    J Natl Cancer Inst. 2025;117:1421-1428.
    PubMed     Abstract available
    
    
    
21. BLEYER A, Ries LAG, Cameron DB, Mansfield SA, et al
    Colon, colorectal, and all cancer incidence increase in the young due to appendix reclassification.
    J Natl Cancer Inst. 2025;117:1340-1349.
    PubMed     Abstract available
    
    
    
22. FAN Q, Dong W, Schafer EJ, Wagle NS, et al
    Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2025;117:1506-1511.
    PubMed     Abstract available
    
    
    June 2025
23. HARLASS M, Knudsen AB, Nieboer D, van Duuren LA, et al
    Benefits of colorectal cancer screening using FIT with varying positivity thresholds by age and sex.
    J Natl Cancer Inst. 2025 Jun 23:djaf149. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. ZAMAN FY, Orchard SG, Polekhina G, Gibbs P, et al
    Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults.
    J Natl Cancer Inst. 2025 Jun 14:djaf145. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. YARMOLINSKY J, Lee MA, Lau E, Moratalla-Navarro F, et al
    Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention.
    J Natl Cancer Inst. 2025 Jun 13:djaf137. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. OVEISI N, Sayre EC, Brotto LA, Cheng V, et al
    Sexual health outcomes after colorectal cancer diagnosis in females: a population-based cohort study.
    J Natl Cancer Inst. 2025 Jun 1:djaf120. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. BYRD DA, Gomez M, Hogue S, Wan Y, et al
    Effects of a high-fiber, high-fruit and high-vegetable, low-fat dietary intervention on the rectal tissue microbiome.
    J Natl Cancer Inst. 2025;117:1237-1244.
    PubMed     Abstract available
    
    
    May 2025
28. 
    Correction to: Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Natl Cancer Inst. 2025 May 30:djaf124. doi: 10.1093.
    PubMed    
    
    
    
29. CHAR SK, Chan JA, Ng K
    Rising incidence of early-onset colorectal cancer: impact of anatomy and histology.
    J Natl Cancer Inst. 2025 May 29:djaf094. doi: 10.1093.
    PubMed    
    
    
    
30. CHEN QY, Keum N, Giovannucci EL
    Post-diagnosis dietary and lifestyle factors and mortality outcomes among colorectal cancer patients: a meta-analysis.
    J Natl Cancer Inst. 2025 May 2:djaf098. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. SOERJOMATARAM I, Bardot A, Bray F
    Stat Bite: Surviving or dying from colon cancer or other causes 5 years after diagnosis, Australia 2010-2014, females.
    J Natl Cancer Inst. 2025;117:1090-1091.
    PubMed    
    
    
    April 2025
32. TSEGAYE AT, Shing JZ, Vo JB, Kreimer AR, et al
    Racial and ethnic differences in HPV-related cancer incidence in the United States, 2001-2020.
    J Natl Cancer Inst. 2025 Apr 26:djaf107. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. MURPHY CC, Dias EM, Cirillo PM, Krigbaum NY, et al
    Father's occupation and colorectal cancer in his adult offspring.
    J Natl Cancer Inst. 2025 Apr 24:djaf104. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. KUMAR R, Hallemeier CL, Chang DT, Lu SE, et al
    Increased occurrence of malignancy before and after chemoradiation for anal squamous cell carcinoma: a multi-institutional analysis.
    J Natl Cancer Inst. 2025;117:772-780.
    PubMed     Abstract available
    
    
    
35. SANTUCCI C, Mignozzi S, Alicandro G, Pizzato M, et al
    Trends in cancer mortality under age 50 in 15 upper-middle and high-income countries.
    J Natl Cancer Inst. 2025;117:747-760.
    PubMed     Abstract available
    
    
    February 2025
36. LIU Y, Song M, Giovannucci EL, Platz EA, et al
    Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study.
    J Natl Cancer Inst. 2025 Feb 25:djaf046. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. HU P, Prorok PC, Katki HA
    Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
    J Natl Cancer Inst. 2025;117:303-311.
    PubMed     Abstract available
    
    
    
38. TROESTER A, Parikh R, Southwell B, Ester E, et al
    Treatment of stage I-III squamous cell anal cancer: a comparative effectiveness systematic review.
    J Natl Cancer Inst. 2025;117:240-252.
    PubMed     Abstract available
    
    
    January 2025
39. MEZGER NCS, Seraphin TP, Balle R, Griesel M, et al
    NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
    J Natl Cancer Inst. 2025;117:120-133.
    PubMed     Abstract available
    
    
    December 2024
40. HU Q, Yang X, Sun Y
    Re: Characteristics of a cost-effective blood test for colorectal cancer screening.
    J Natl Cancer Inst. 2024 Dec 24:djae340. doi: 10.1093.
    PubMed    
    
    
    
41. LI X, Hur J, Zhang Y, Song M, et al
    Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women.
    J Natl Cancer Inst. 2024 Dec 17:djae330. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2024
42. JUDGE SJ, Malekzadeh P, Corines MJ, Gollub MJ, et al
    Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy.
    J Natl Cancer Inst. 2024;116:1761-1766.
    PubMed     Abstract available
    
    
    October 2024
43. DOWNIE JM, Joshi AD, Geraghty CM, Guercio BJ, et al
    Novel metabolomic predictors of incident colorectal cancer in men and women.
    J Natl Cancer Inst. 2024 Oct 28:djae270. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. HU Q, Zhou X, Sun Y
    RE: Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).
    J Natl Cancer Inst. 2024 Oct 16:djae257. doi: 10.1093.
    PubMed    
    
    
    
45. VAN DEN PUTTELAAR R, Shi KS, Smith R, Zhao J, et al
    Implications of the initial braidwood v. Becerra ruling for colorectal cancer outcomes: a modeling study.
    J Natl Cancer Inst. 2024 Oct 3:djae244. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    PubMed     Abstract available
    
    
    September 2024
47. ZHAO J, Xue E, Zhou S, Zhang M, et al
    Allostatic Load, Genetic Susceptibility, Incidence Risk, and All-cause Mortality of Colorectal Cancer.
    J Natl Cancer Inst. 2024 Sep 13:djae223. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. GARG A, Damgacioglu H, Sigel K, Nyitray AG, et al
    Future patterns in burden and incidence of squamous cell carcinoma of the anus in the United States, 2001-2035.
    J Natl Cancer Inst. 2024;116:1508-1512.
    PubMed     Abstract available
    
    
    
49. DESHMUKH AA, Lin YY, Damgacioglu H, Shiels M, et al
    Recent and projected incidence trends and risk of anal cancer among people with HIV in North America.
    J Natl Cancer Inst. 2024;116:1450-1458.
    PubMed     Abstract available
    
    
    August 2024
50. CHENG E, Ou FS, Gatten C, Ma C, et al
    Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer.
    J Natl Cancer Inst. 2024 Aug 30:djae213. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. BROWN JC, Ma C, Shi Q, Couture F, et al
    Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
    J Natl Cancer Inst. 2024 Aug 24:djae203. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. LIANG PS, Bhatt D
    Modeling disparities in colorectal cancer outcomes: colonoscopy follow-up and quality are key.
    J Natl Cancer Inst. 2024 Aug 8:djae176. doi: 10.1093.
    PubMed    
    
    
    
53. RIM SH, Beer L, Saraiya M, Tie Y, et al
    Prevalence of anal cytology screening among persons with HIV and lack of access to high-resolution anoscopy at HIV care facilities.
    J Natl Cancer Inst. 2024;116:1319-1332.
    PubMed     Abstract available
    
    
    
54. GUPTA A, O'Callaghan CJ, Zhu L, Jonker DJ, et al
    The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17.
    J Natl Cancer Inst. 2024;116:1313-1318.
    PubMed     Abstract available
    
    
    
55. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available
    
    
    
56. BERRY E, Hostetter J, Bachtold J, Zamarripa S, et al
    Evaluating colonoscopy quality by performing provider type.
    J Natl Cancer Inst. 2024;116:1264-1269.
    PubMed     Abstract available
    
    
    July 2024
57. ALAGOZ O, May FP, Doubeni CA, Fendrick AM, et al
    Impact of racial disparities in follow-up and quality of colonoscopy on colorectal cancer outcomes.
    J Natl Cancer Inst. 2024 Jul 24:djae140. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
58. TSAI YY, Nair KG, Barot SV, Xiang S, et al
    Differences in Tumor-Associated T cell receptor repertoires between Early-Onset and Average-Onset colorectal cancer.
    J Natl Cancer Inst. 2024 Jun 20:djae143. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. SONG Y, Loomans-Kropp H, Baugher RN, Somerville B, et al
    Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome.
    J Natl Cancer Inst. 2024;116:957-965.
    PubMed     Abstract available
    
    
    
60. YATES J, Schaufelberger H, Steinacher R, Schar P, et al
    DNA-methylation variability in normal mucosa: a field cancerization marker in patients with adenomatous polyps.
    J Natl Cancer Inst. 2024;116:974-982.
    PubMed     Abstract available
    
    
    
61. RANSOHOFF DF
    Evaluating a blood test for Colon cancer screening: how simulation modeling can inform clinical policy making and research.
    J Natl Cancer Inst. 2024 Jun 6:djae125. doi: 10.1093.
    PubMed    
    
    
    
62. NASCIMENTO DE LIMA P, Van Den Puttelaar R, Knudsen AB, Hahn AI, et al
    Characteristics of a cost-effective blood test for colorectal cancer screening.
    J Natl Cancer Inst. 2024 Jun 6:djae124. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
63. HOCHSTER HS, Catalano P, Weitz M, Mitchell EP, et al
    Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208).
    J Natl Cancer Inst. 2024 May 22:djae114. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. CORONADO GD, Bienen L, Burnett-Hartman A, Lee JK, et al
    Maximizing scarce colonoscopy resources: the crucial role of stool-based tests.
    J Natl Cancer Inst. 2024;116:647-652.
    PubMed     Abstract available
    
    
    April 2024
65. SUN J, Zhao J, Zhou S, Li X, et al
    Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer.
    J Natl Cancer Inst. 2024 Apr 22:djae089. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. FANG A, Ugai T, Gurjao C, Zhong R, et al
    Alcohol and colorectal cancer risk subclassified by mutational signatures of DNA mismatch repair deficiency.
    J Natl Cancer Inst. 2024 Apr 4:djae078. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
67. BEVER AM, Hang D, Lee DH, Tabung FK, et al
    Metabolomic signatures of inflammation and metabolic dysregulation in relation to colorectal cancer risk.
    J Natl Cancer Inst. 2024 Mar 1:djae047. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. GOPALANI SV, Saraiya M, Huang B, Tucker TC, et al
    Population-level incidence of HPV-positive oropharyngeal, cervical, and anal cancers by smoking status.
    J Natl Cancer Inst. 2024 Mar 1:djae054. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.